SCHEMBL3777976

SCHEMBL3777976

Cc1cc(OCC(=O)O)c2c(C)c(Cc3ccc(Cl)cc3)c(C)nc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.44
TSHR P16473 1/20 0.44
PLA2G2A P14555 2/20 0.43
PKM P14618 1/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
THRA P10827 1/20 0.40
THRB P10828 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.39
PPARG P37231 1/20 0.39
PPARD Q03181 2/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PLA2G10 O15496 1/20 0.38
PLA2G1B P04054 1/20 0.38
PLA2G5 P39877 1/20 0.38
PLA2G2E Q9NZK7 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3777108 0.90 ALDH1A1 (0.44) TSHRPLA2G2APKMKDM4EALDH1A1
SCHEMBL27826430 0.85 PLA2G2A (0.42) PLA2G2APKMKDM4EALDH1A1HPGD
SCHEMBL27743397 0.83 PLA2G2A (0.41) PLA2G2APKMKDM4EALDH1A1HPGD
SCHEMBL3776046 0.83 TDP1 (0.46) TDP1TSHRPLA2G2APKMKDM4E
SCHEMBL3780495 0.81 PTGDR2 (0.48) PLA2G2AKDM4EPTGDR2KMT2A
SCHEMBL3779792 0.81 ALDH1A1 (0.44) TSHRPLA2G2APKMKDM4EALDH1A1
SCHEMBL3779168 0.80 TDP1 (0.45) TDP1TSHRTHRATHRBPTGDR2
SCHEMBL3779606 0.79 PLA2G2A (0.37) TDP1PLA2G2AKDM4EALDH1A1KMT2A
SCHEMBL3788414 0.78 RORC (0.41) TDP1PLA2G2AKDM4EALDH1A1HPGD
SCHEMBL5329822 0.78 PKM (0.61) TSHRPKMKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 TDP1 4824/4885TSHR 73/4885PLA2G2A 1779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.